Muscarinic cholinergic receptors in the normal and neurogenic human bladder.
Bladder dysfunction secondary to neurologic conditions occurs in all age groups and is associated with significant morbidity. The role of neuroreceptors in the development of detrusor dysfunction has not been studied previously. Control bladder tissue specimens were obtained from eight children with ureterovesical reflux undergoing ureteral reimplantation and 14 adults with bladder carcinoma undergoing cystectomy. Neurogenic bladder specimens were obtained from 10 children with myelomeningocele and five adults with neurogenic bladder dysfunction undergoing augmentation cystoplasty. Saturation experiments using 3H-N-methylscopolamine (3H-NMS) were performed in these control and neurogenic bladder homogenates. The mean equilibrium dissociation constants in the neurogenic and control bladders were 0.41 nM and 0.55 nM, respectively. The mean density of muscarinic cholinergic (MCh) receptor binding sites in the neurogenic and control bladders was 0.34 fmol/mg wet wt. and 0.65 fmol/mg. wet wt., respectively. Competitive binding experiments with 3H-NMS and various unlabelled MCh antagonists indicated that the pharmacology of MCh binding sites was similar in neurogenic and control bladders. Age was not significantly correlated with MCh receptor density in the control and neurogenic bladders. Muscarinic cholinergic binding sites are homogeneous in neurogenic and control bladders. The lower density of MCh receptors in the neurogenic bladders may represent down regulation of MCh receptors or a replacement of smooth muscle by fibrosis.
Lepor
H
H
Dept. of Urology, Jewish Hospital of St. Louis, MO 63178.
Gup
D
D
Shapiro
E
E
Baumann
M
M
D000328:Adult; D000375:Aging / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D002648:Child; D002675:Child, Preschool; D006801:Humans; D019832:N-Methylscopolamine; D010276:Parasympatholytics / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000378:metabolism*; D012016:Reference Values; D012602:Scopolamine Derivatives / Q000378:metabolism; D001743:Urinary Bladder / Q000378:metabolism*; D001750:Urinary Bladder, Neurogenic / Q000378:metabolism*
D010276:Parasympatholytics; D011976:Receptors, Muscarinic; D012602:Scopolamine Derivatives; D019832:N-Methylscopolamine